Global Treatment for Syndromes of Dementia and Movement Disorders Market Report, published by Variant Market Research, forecast that the global market is expected to reach $28.6 Billion by 2024 from $14.5 Billion in 2016, growing at a CAGR of 8.9% from 2016 to 2024. By geography, Asia-Pacific and Europe are expected to grow at a CAGR of 9.9% and 9.1%, respectively, during the forecast period.
"Treatment for Syndromes of Dementia and Movement Disorders Market (By Type: Movement Disorders, Progressive Dementia, and Progressive Dementia with Neurological Abnormalities; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend, and Forecast, 2015-2024"
The factors supporting the growth of the market include rising geriatric population, increasing knowledge and accessibility towards various healthcare services such as homecare services and psychological services, growing investments in R&D, and increasing rate of neurodegenerative disorders. Though, lack of appropriate disorder management and long approval time for drugs and devices could limit the growth of the market. Additionally, untapped markets, especially in emerging economies and several awareness programs to improve the level of knowledge would provide growth prospects for the market in the forecast period 2016 – 2024.
Type and geography are the two major segments considered in the global treatment for syndromes of dementia and movement disorders market. By type, the segment is categorized into movement disorders (Parkinson’s disease, progressive supranuclear palsy, multiple system atrophy, hallervorden-spatz disease and others), progressive dementia (Alzheimer’s disease, Lewy body dementia, frontotemporal dementia/pick and others) and progressive dementia with neurological abnormality (Huntington’s disease, corticobasal ganglionic degeneration, amyotrophic lateral sclerosis(ALS)). Among which, progressive dementia is anticipated to dominate the market with highest revenue from 2015 to 2024.
By geography, the market has been bifurcated into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America accounted for the largest market share with 42.2% in 2016, driven by presence of large number of elderly population, increasing R&D investments, and unhealthy lifestyles, followed by Europe with 25.8%. In terms of growth, Asia-Pacific is expected to grow with fastest CAGR, owing to, presence of large population base, increasing knowledge, and expanding healthcare facilities.
Major players in the market include Valeant Pharmaceutical International, AstraZeneca GmbH, F. Hoffmann-La Roche, AG, Abbott Laboratories, Inc., Merck & Co., Inc., Sanofi S.A., Novartis AS, Bristol-Myers Squibb, Baxter International, Inc., and Pfizer, Inc., among others.